Mirae Asset Global Investments Co. Ltd. Purchases 2,837 Shares of Natera, Inc. $NTRA

Key Points

• Mirae Asset Global Investments Co. Ltd. increased its stake in Natera, Inc. by 5.0%, purchasing an additional 2,837 shares, bringing its total holdings to 59,808 shares valued at about $10.1 million.
• Natera recently reported earnings of ($0.74) EPS, missing estimates, but saw a 32.2% increase in revenue year-over-year, amounting to $546.6 million.
• Analysts have expressed a positive outlook on Natera, with multiple firms issuing ratings ranging from "overweight" to "strong-buy" and an average price target of $192.88.

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 59,808 shares of the medical research company's stock after purchasing an additional 2,837 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Natera were worth $10,104,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Guided Capital Wealth Management LLC lifted its holdings in shares of Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock worth $2,219,000 after buying an additional 66 shares in the last quarter. Wedmont Private Capital raised its stake in Natera by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company's stock worth $256,000 after purchasing an additional 74 shares in the last quarter. Compound Planning Inc. boosted its holdings in Natera by 4.2% in the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock valued at $271,000 after purchasing an additional 78 shares during the period. QRG Capital Management Inc. grew its position in shares of Natera by 1.5% during the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after purchasing an additional 81 shares in the last quarter. Finally, Earned Wealth Advisors LLC grew its position in shares of Natera by 5.0% during the 1st quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock worth $246,000 after purchasing an additional 82 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $167.35 on Monday. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00. The firm has a market cap of $22.97 billion, a PE ratio of -87.62 and a beta of 1.74. The firm's fifty day moving average is $161.17 and its 200-day moving average is $156.66.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on NTRA. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Wells Fargo & Company initiated coverage on Natera in a report on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 price objective for the company. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 target price for the company in a research report on Monday, July 28th. Stephens restated an "overweight" rating and issued a $183.00 price target on shares of Natera in a research report on Friday, August 15th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $220.00 price objective (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $192.88.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $132.89, for a total value of $398,670.00. Following the sale, the insider directly owned 123,059 shares in the company, valued at $16,353,310.51. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 3,045 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares of the company's stock, valued at approximately $8,990,082. The trade was a 4.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,464 shares of company stock valued at $10,963,125 in the last ninety days. Insiders own 5.63% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.